In SLE and healthy donors, CXCR3 results demonstrated that probiotic treated groups had a lower expression compared with the LPS treated group, in which the reduced expression can be due to the tolerogenic effect of used probiotics during the maturation process of DC and shifting to regulatory properties, including low expression of surface markers including CXCR3. The gene discussed is CXCR3; the disease is systemic lupus erythematosus.